such as redness and pain are reported in approximately 2.1-4.3% of cases.

History

Patent dispute

Regeneron Pharmaceuticals and Amgen each filed for US patent protection on their monoclonal antibodies against PCSK9, leading to patent litigation. In March 2016, a district court found that Regeneron's drug alirocumab